The cannabis plant has a long and extensive ethno-botanical history dating back many years and throughout varied and diverse cultures. The plant contains a number of different therapeutically active components which are referred to as cannabinoids. The scientific and medical research of the cannabis plant has been complicated by the social and legal issues surrounding it. However, there is compelling evidence that there are medical indications and therapeutic benefits associated with the plant and specific cannabinoids within. Still, the exact mechanism(s) of action or specific component(s) of the cannabis plant involved in generating these beneficial effects is not clear. Today, there are literally hundreds, perhaps thousands of cannabis strains, each with its own unique balance of cannabinoids and potencies. Each strain, which may contain cannabinoids in a specific and unique ratio, has the potential to produce varied outcomes when used. The best known of these compounds is THC, which is associated with the psychoactive properties of the plant. More recently, a compound known as CBD has been a focus of significant research relating to its beneficial effects in the treatment of certain types of epilepsy and inflammation.
However, while a growing number of physicians and patients are also turning to “medical marijuana” for treating health conditions, a recent report from Morgan Stanley stated “physicians expressed concerns about batch-to-batch fluctuations in “medical marijuana” potency with no clarity on what drives the differences. Additionally, as there has been no dosing work done with “medical marijuana”, physicians are not clear if they are prescribing the proper dose to patients and if patients will receive the same exact drug across doses”. Such clarity in view of the rising demand for cannabis will further be stimulated by the massive size of the baby boomer population, as use of marijuana for medical purposes becomes more acceptable. This has significant implications for companies that can provide product(s) that physicians will feel comfortable in prescribing. Because of the nascent stage of the regulated market, however, there are few standards in place to assure proper potency, safety and quality control. Even fewer regulations exist which define what growers and distributors may claim when selling “medical marijuana”.
In response to the current deficiencies in the marketplace, CannRx has established a business model that addresses these market needs. The Company's strategy employs components that include developing first-to-market quality testing assays, providing a scientific method to streamline cannabis growth and utilizing a novel analytic approach to develop therapeutic cannabis products. As a result, CannRx is able to differentiate itself from current “medical marijuana” companies.
CannRx projects that two distinct trends will occur in the cannabis market. The current “medical marijuana” market is growing rapidly and becoming more sophisticated. Both medical professionals and patients are increasing their demand for a product with defined; clear indications, dosing instructions and clinical outcomes that meet the highest level of safety and efficacy. The current model of “one size fits all” and superficial analyses of currently marketed products fall far short of this demand.
CannRx intends to use its differentiated platform (versus “medical marijuana”) to (a) provide consistency and predictability of doses, (b) define the profile of product composition and (c) optimize dosing administration. Together this will provide therapies that attain significant commercial success as a result of being FDA-approved, covered by third party payors (insurance) and accepted by clinicians and patients.
CannRx Technology Inc.
One Rockefeller Plaza, 11th Floor
New York, NY 10020
© 2016 Copyright by CannRx Technology Inc. All Rights Reserved.